Is Acute Myeloid Leukemia M2b Curable?

Acute myeloid leukemia (AML) subtype M2B—now classified under the broader category of AML with abnormal bone marrow eosinophils and CBFB-MYH11 fusion gene—is a distinct molecular and morphologic variant of AML. Historically designated as M2B in the French-American-British (FAB) classification system, this subtype is characterized by the presence of maturing granulocytes, ≥20% blasts in the bone marrow, and a characteristic inv(16)(p13.1q22) or t(16;16)(p13.1;q22) chromosomal rearrangement, which results in the CBFB-MYH11 fusion transcript.

Prognostically, AML with CBFB-MYH11 is considered favorable-risk according to current European LeukemiaNet (ELN) and National Comprehensive Cancer Network (NCCN) guidelines. Patients typically exhibit high rates of complete remission following standard induction chemotherapy—most commonly cytarabine combined with an anthracycline (e.g., “7+3” regimen). Long-term outcomes are notably better than those seen in many other AML subtypes: five-year overall survival rates often exceed 60–70% in younger, fit adults, and relapse risk remains relatively low with appropriate consolidation therapy, including high-dose cytarabine.

While “curable” is a cautious term in oncology, a substantial proportion of patients with this subtype achieve durable remission and potential cure, particularly when treated at experienced centers and adhering to evidence-based protocols. However, outcomes remain influenced by age, performance status, comorbidities, and the presence of additional adverse genetic lesions—such as KIT mutations, which may confer higher relapse risk and warrant closer monitoring or investigational approaches.

In summary, AML with CBFB-MYH11 (formerly FAB M2B) is among the most treatable forms of AML, with robust response to conventional chemotherapy and favorable long-term survival prospects. Accurate molecular diagnosis—including cytogenetic analysis and RT-PCR or next-generation sequencing for CBFB-MYH11—is essential to guide risk stratification and therapeutic decisions.